PTA-126817(ATCC)
No.22547(CGMCC)
Function
● Alleviate diarrhea
● Relieve constipation
● Mitigate irritable bowel syndrome (IBS)
● Inhibit anti-helicobacter pylori (H. pylori) activity
*This statement has not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Clinical Study:
Diarrhea: Interventional study of Bifidobacterium animalis subsp. lactis BLa80 in improving acute watery diarrhea in children
Constipation: Efficacy, safety, and acceptability of the probiotic Bifidobacterium animalis subsp. lactis BLa80 in regulating gut habits in chronic constipation patients
Anti-H. pylori: Effects of probiotics combined with bismuth quadruple therapy on the gut microbiota during eradication of Helicobacter pylori
Immune Boosting: Safety and efficacy of Bifidobacterium animalis subsp. lactis BLa80 in modulating gut microbiota and immune function: a randomized, double-blind, placebo-controlled clinical trial (in progress)
Relief of IBS-D: Randomized, double-blind, placebo-controlled trial investigating the effects of Bifidobacterium animalis subsp. lactis BLa80 on diarrhea-predominant irritable bowel syndrome (IBS-D) and gut microbiota modulation (in progress)
Patent:
CN114146101B
The Application of Bifidobacterium lactis BLa80 in the Production of Pharmaceuticals or Foods for Regulating Intestinal Motility.
CN114146100B
The Application of Bifidobacterium lactis BLa80 in the Production of Pharmaceuticals for Treating Rotavirus Infection-Induced Diarrhea.
CN113430133B
A Compound Probiotic for Alleviating Ulcerative Colitis, Preparation Method, and Its Application.
CN113265361B
A Compound Probiotic Preparation for Alleviating Non-Alcoholic Fatty Liver Disease, Preparation Method, and Its Application.
CN113913322B
The Application of Bifidobacterium lactis BLa80 in Alleviating Diarrhea and Enhancing Intestinal Immune Function.
CN113265361B
A Compound Probiotic Formulation for Alleviating Non-Alcoholic Fatty Liver Disease, Preparation Method, and Its Application.
SCI:
Dysbiosis of Gut Microbiota Is Associated With the Progression of Radiation-Induced Intestinal Injury and Is Alleviated by Oral Compound Probiotics in Mouse Model.
Bifdobacterium BLa80 mitigates colitis by altering gut microbiota and alleviating infammation.
